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Abstract
Aims/hypothesis The Trial to Reduce IDDM in the Genet-
ically at Risk (TRIGR) study was designed to establish
whether weaning to a highly hydrolysed formula in infancy
subsequently reduces the risk of type 1 diabetes.
Methods The study population comprises newborn infants
who have first-degree relatives with type 1 diabetes and
meet the increased risk HLA inclusion, but not exclusion
criteria. The study is being performed in 15 countries in
three continents. First-degree relatives of patients with type
1 diabetes were identified from diabetes clinics, diabetes
registries, and from other endocrinology or obstetrics
offices and websites. HLA typing was performed at birth
from cord or heel stick blood, and the results sent to the
study’s Data Management Unit within 2 weeks for
communication of eligibility to the clinical study centre.
All mothers recruited were encouraged to breastfeed. The
intervention lasted for 6 to 8 months, and weaning formulas
based on hydrolysed casein and standard cow’s milk were
compared.
Results TRIGR recruited 5,606 infants, of whom 2,160
were enrolled as eligible participants, 6% more than the
target of 2,032. Of those enrolled, 80% were exposed to the
study formula. The overall retention rate over the first
5 years is 87%, with protocol compliance at 94%. The
randomisation code will be opened when the last recruited
child turns 10 years of age, i.e. in 2017.
Conclusions/interpretation The TRIGR experience demon-
strates the feasibility and successful implementation of an
international dietary intervention study. TRIGR is the first
ever primary prevention trial for type 1 diabetes and, if
completed successfully, will provide a definite answer to
the research question.
Trial registration ClinicalTrials.gov NCT00179777
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Introduction
The Trial to Reduce IDDM in the Genetically at Risk
(TRIGR) study is an international randomised double-blind
controlled intervention trial that was designed to establish
whether weaning to a highly hydrolysed formula in infancy
reduces the risk of type 1 diabetes later in childhood [1, 2].
This report describes completion of recruitment, the
intervention and current follow-up status.
The specific TRIGR aims are: (1) to determine whether
weaning to a formula comprised of hydrolysed protein,
compared with a standard intact foreign cow’s milk protein
formula, reduces the cumulative incidence of diabetes-
predictive autoantibodies and/or clinical diabetes over the
first 6 years of life; and (2) to assess whether weaning to the
hydrolysate reduces the cumulative incidence of type 1
diabetes in these participants by 10 years of age. The
novelty of this approach is that it represents the first-ever
appropriately powered primary prevention trial for type 1
diabetes and that it is being implemented across several
continents.
Methods
Participants and study design The study design has
previously been described in detail [1, 2]. In brief, the
TRIGR study population comprises newborn infants who
have first-degree relatives with type 1 diabetes (i.e. mother,
father or sibling) and who meet the HLA inclusion but none
of the exclusion criteria. Blood for analysis of HLA
genotypes was collected and sent to the continental central
laboratory within 8 days of birth and results sent to the Data
Management Unit (DMU) within 2 weeks of age for
assessment and confirmation of eligibility, which were then
forwarded electronically to the participating centres. This
international, double-blinded, prospective, placebo-
controlled intervention trial comprises 77 centres (or sites)
in 15 countries on three continents (Table 1). Enrolment
began on 1 May 2002 and ended on 6 February 2007. Each
site obtained appropriate approval from an Ethical Com-
mittee or Institutional Review Board (IRB). For details of
TRIGR investigators and staff members, see Electronic
supplementary material (ESM) Tables 1 and 2.
Recruitment and randomisation First-degree relatives of
patients with type 1 diabetes were identified from a variety
of sources, including: (1) existing diabetes registries; (2)
parents of patients attending paediatric diabetes clinics; (3)
prospective parents attending obstetric clinics prior to
delivery; (4) prospective parents attending diabetes clinics;
(5) local and national advertising; and (6) diabetes societies.
In some countries the presence of type 1 diabetes in a
mother or father was identified only at the time of birth and
appropriate consent was obtained at that time; otherwise
consent was obtained during pregnancy. When we first
started, there were 11 participating countries with one or
more sites each with IRB approval. Within 6 months, the
number of enrolling centres grew to 45 (final number 77).
Because of the recruitment success, the enrolment target
was exceeded by 6% to 2,160. Due to demographics, 2,076
(96 %) of the randomised participants included were white.
The children were randomly assigned to the two
treatment groups in a 1:1 ratio using randomly permuted
blocks [1]. Randomisation was balanced within each
participating centre/country. Web-based randomisation pro-
cedures were implemented efficiently. Babies were assigned
one of four colour-coded, blinded formulas, two of which
contained the hydrolysed test formula, two the control
formula. The randomisation code was known only to the
manufacturer and the Principal Investigator of the DMU,
under supervision of the Data Safety and Monitoring Board
(DSMB).
Sample size and power The following background factors
were considered when planning the sample size: expected
rates of background breastfeeding; non-adherence to the
intervention (in 16–17% of participants the intervention
was non-existent or shorter than 2 months in the second
pilot study [3]); losses to follow-up; and HLA ineligibility.
The sample size and power calculations have been
described in detail earlier [1].
More recent updates from the Diabetes Auto Immunity
Study in the Young (DAISY), Untersuchungen bei Kindern
von Müttern mit Typ-1-Diabetes (BABYDIAB-Study) and
Diabetes Prediction and Prevention Study (DIPP) confirm
the frequencies of autoantibodies used in our sample size
estimate [4–6]. In the DIPP study, 188 young children with
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a family member affected by the disease and HLA-
conferred disease susceptibility were observed up to the
average age of 3 years. Among them, 15 (8%) serocon-
verted to persistent positivity for at least two of the
following autoantibodies: islet cell antibodies, insulin
autoantibodies, GAD antibodies and islet antigen 2 anti-
bodies [6].
Assuming a linear increase over the next 3 years, 16%
can be expected to test persistently positive for at least two
autoantibodies by the age of 6 years. The cumulative
incidence of persistent positivity for at least two antibodies
was 12.5% by the age of 6 years in the TRIGR pilot study
[3].
The projected sample size of 2,032 infants to be rando-
mised for the trial is based on the following assumptions: (1) a
confidence level of 95%; (2) a statistical power of 80%; (3) a
reduction of 40% in the hazard rate of type 1 diabetes in the
intervention group; (4) a dropout rate of 20%; and (5) a
frequency of 10% of exclusive breastfeeding up to the age of
6 months. In our study protocol we estimated that the 6 year
endpoint based on positivity for two or more autoantibodies
would require a sample size of 1,334 children [2].
HLA typing Cord blood was obtained whenever possible,
but if unobtainable, a heel stick blood sample was collected
on filter paper and immediately sent to the Turku
(Europe and Australia) or Pittsburgh (North America)
laboratories for HLA genotyping. HLA genotyping for
the selected DQB1 and DQA1 alleles was performed using
sequence-specific oligonucleotide hybridisation, with quality
control between the two laboratories carefully maintained.
The following genotypes were regarded as eligible: (1) HLA-
DQB1*02/DQB1*0302; (2) HLA-DQB1*0302/x (x not
DQB1*02, DQB1*0301 or DQB1*0602); (3). HLA-
DQA1*05-DQB1*02/y (y not DQA1*0201-DQB1*02,
DQB1*0301, DQB1*0602 or DQB1*0603); (4) HLA-
DQA1*03-DQB1*02/y (y not DQA1*0201-DQB1*02,
DQB1*0301, DQB1*0602 or DQB1*0603).
Parents of ineligible infants were informed that genetic
screening suggested no increased susceptibility to type 1
diabetes in their child(ren) and were thanked for their
participation. It was emphasised that their child could still
develop diabetes despite not meeting the eligibility criteria.
The acceptability of this strategy was evident from the fact
that many families volunteered for screening of a second
child born after the ineligible infant [2].
Study materials A team of TRIGR investigators, as well as
staff of the International Coordinating Centre (ICC) and the
Nutritional Epidemiology Unit in collaboration with the
DMU in Tampa, FL, USA, prepared the Manual of
Operations and the various forms. While the official trial
language was English, forms and dietary advice leaflets
were double-translated into 11 languages and adapted to
national practices. It took only 6 months to create the
website, develop forms and the Manual of Operations, and
to train staff around the world. The Manual of Operations is
available to TRIGR Study Group Members.
Intervention Whenever supplementary milk feeding was
needed during the intervention period, participants received
either the test formula based on extensively hydrolysed
casein (Nutramigen; Mead Johnson Nutrition, Evansville,
IN, USA) or a control formula created by the company for
this study and made with intact (80%, wt/wt) and hydro-
lysed (20%, wt/wt) milk protein to mask the taste and smell
Country Recruitment (n) Enrolment (n) Eligibility (%) Lost to follow-upa Not participatinga
Australia 298 103 39.9 8
Canada 1,423 531 42.2 17 50
Czech Republic 412 164 40.3 10
Estonia 98 35 42.2 3
Finland 1,037 424 45.5 43
Germany 287 112 41.3 1 14
Hungary 66 23 36.5 2 4
Italy 149 54 42.5 1 15
Luxembourg 14 7 50.0
Netherlands 136 51 40.2 1
Poland 250 95 42.6 33
Spain 133 60 47.2 9
Sweden 209 97 51.6 13
Switzerland 26 13 52.0 2
USA 1,068 391 43.5 14 44
Total 5,606 2,160 43.2 35 249
Table 1 Achieved rates of
recruitment, enrolment, HLA
eligibility (%) and numbers of
lost to follow-up participants
and non-participants by country
a 31 May 2010
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differences between the two formulas. All recruited mothers
were encouraged to breastfeed their infants. The study
formulas and the implementation of intervention have been
described earlier [1].
Exclusive breastfeeding was defined as absence of any
food other than breast milk (banked or mother’s), supple-
mentary vitamins or minerals, or water.
The study formulas were packed in four different
colours, two for test formula and two for control formula,
aiding the blinding process and also providing a hard
control for randomisation during data analysis [1]. Import
of the coded study formulas to different countries required a
major effort to overcome barriers such as customs and
storage regulations.
Follow-up during and after intervention Clinical assess-
ment, interviews and blood sampling were performed at the
ages of 3, 6, 9, 12, 18 and 24 months (at a study centre or a
home visit), and will continue annually until 10 years of
age or until manifestation of type 1 diabetes as outlined
below. Clinical data at each visit (e.g. weight, height,
adverse events, infections etc.) are recorded and transmitted
electronically to the DMU. Cow’s milk antibodies (IgG and
IgA) [7] and α-casein antibodies (IgG and IgA) [8] were
measured within 2 months of sampling up to the 9-month
visit for use as markers of efficacy of and compliance with
the intervention, while other laboratory tests are scheduled
in batches. A heparin blood sample is obtained at each
sampling time. These samples are sent fresh to the core
laboratories in Helsinki and Toronto for isolation of
mononuclear cells for mechanistic studies of T cell
responses. Local measurements of random plasma glucose
and glycosylated haemoglobin are performed at each visit
from 12 months onwards and reported to the DMU. The
specimen for plasma glucose is preferentially obtained 1 to
2 h postprandially. In the presence of hyperglycaemia or
elevated glycosylated haemoglobin, an OGTT is recom-
mended to exclude or confirm diagnosis of diabetes. An
OGTT is performed in all non-diabetic participants at the
age of 6 and 10 years. If the first OGTT meets WHO
criteria for diagnosis of diabetes [9], a second confirmatory
test is performed to verify the diagnosis.
The success of the study depends on at least 80% of the
children being retained in follow-up to the age of 10 years,
with compliance with blood draws (HLA and antibody
samples). Strategies successfully implemented in this
respect include frequent family phone contacts, newsletters,
distribution of TRIGR calendars with reminders and
incentives such as birthday cards, study centre parties,
websites and active assistance with surveillance of the
health of the participating child. The DMU has developed
an automated reminder system that repeatedly notifies each
centre electronically when each of its participants is due for
a visit, and monitors compliance regularly.
Results
Recruitment and randomisation TRIGR recruited 5606
infants, of whom 5001 were randomised (Fig. 1). In the
605 participants (10.8 % of those recruited) not rando-
mised, non-randomisation was mainly due to preterm births
(41%) and families changing their minds about participation.
The study enrolled 2,160 participants, 6% above the target of
2,032 eligible participants achieved in less than 5 years. The







Newborn infants who fulfil the inclusion criteria and whose parents have given their consent, n=5,001
Risk genotypes: HLA-DQB1*02/0302 
HLA-DQB1*0302/x (x=DQB1*02, *0301, *0602) 
HLA-DQA1*05-DQB1*02/y (y=DQA1*0201-DQB1*02, DQB1*0302, *0301, *0602, *0603)   





Group A Group B
n=1,081 n=1,079
















Fig. 1 Trial profile for the
participants in TRIGR study
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Table 1, which shows that the countries with the highest
recruitment and enrolment were Canada, Finland and theUSA.
For data analyses, countries were grouped by region (Table 2).
Dropouts The dropouts belong to one of the following two
categories: (1) non-participants, i.e. participants/families
that do not wish to participate further in study interviews
and/or testing; or (2) those lost to follow-up, i.e. partic-
ipants/families lost to follow-up because the family cannot
be located, does not respond to study centre inquiries or in
any other way refuses all contacts concerning TRIGR.
The number of dropouts is presented by country in
Table 1.
Diabetes in the family A breakdown of the diabetic
relatives of trial participants by country is presented in
ESM Table 3. Mothers with type 1 diabetes were the most
common, reflecting recruitment strategies and effectiveness.
Finland was an exception, with fathers being the most
frequent first-degree relatives (53 %).
HLA eligibility The HLA eligibility percentages are shown
by country in Table 1. There were no significant differences
in the proportion of HLA-eligible participants between
various regions or countries. However, there was a highly
significant (p<0.0001) heterogeneity in the distribution of
the three major eligible HLA genotype groups. The
frequencies in European countries (grouped into northern,
central and southern Europe), and in Australia, Canada and
the USA are presented in Table 2. The differences were
mainly due to the higher proportion of the DQA1*05-
DQB1*02 haplotype in southern Europe, whereas
DQB1*0302-positive haplotypes were more common in
northern Europe (Table 2). The distribution in Australia was
quite close to that in southern European, whereas the
haplotype frequencies in Canada, USA and central Europe
were similar.
Dietary compliance Dietary compliance was excellent.
Exposure to the Study Formula was 80% exposure, with a
3.6% rate of exclusive breastfeeding until the age 6 months
(lower than the predicted frequency of 10%). Exposure to
non-recommended formulas during the first 3 days of life
was only 3.5%, with cumulative exposure to non-
recommended foods among all the participants reaching
16.3% by the end of the intervention. Study Formula
intolerance was suspected in 5.7% of the participating
infants. These results are well within the range specified by
the study design. Breast-feeding rates were high in the
present study population. Thus 86.9% of mothers with type
1 diabetes and 93.9% of mothers without type 1 diabetes
started to breastfeed, with 51.2% and 70.8%, respectively,
continuing to breastfeed when the child was 6 months old.
Antibodies to cow’s milk proteins Analysis of cow’s milk
antibodies from sera collected as part of the study visits
between the age of 3 and 9 months substantiates the self-
reported dietary and study formula intake collected as
part of the study visits between the age of 3 and
9 months. The results are consistent with the reported
dietary consumption of food products containing cow’s
milk or its derivative, with median values near zero
before cow’s milk introduction and rising significantly
thereafter. Because of continued blinding, data by
intervention group have not been released.
Overall study retention Currently 86.9% of the original
participants are actively participating in the study. The lost
Table 2 Eligible genotypes by European regions, Australia, Canada and the USA
Region HLA-DQ genotype
DQB1*02/DQ B1*0302 DQB1*0302/x DQA1*05-DQB1*02/y DQA1*03-DQB1*02/y All
n % n % n % n % n
Northern Europea 103 18.5 309 55.6 144 25.9 0 0.0 556
Central Europeb 116 25.0 210 45.1 135 29.0 4 0.9 465
Southern Europec 33 29.0 36 31.6 44 38.6 1 0.9 114
Australia 24 23.3 35 34.0 44 42.7 0 0.0 103
Canada 144 27.1 196 36.9 182 34.3 9 1.7 531
USA 96 24.6 167 42.7 120 30.7 8 2.1 391
Total 516 23.9 953 44.1 669 31.0 22 1.0 2,160
Values are n (%); χ2 test=67.791, df=15, p<0.0001
a Northern Europe: Estonia, Finland and Sweden; b Central Europe: Czech Republic, Germany, Hungary, Luxembourg, the Netherlands, Poland and
Switzerland; c Southern Europe: Italy including Sardinia and Spain
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to follow-up rates are low (1.6%), but 11.5% are currently
not participating. Data presented by country are shown in
Table 1. North America had a higher proportion of children
lost to follow-up (3.3% vs 0.3%; p<0.001) and a lower
proportion of non-participating children (9.9% vs 12.5%;
p=0.06) than Europe and Australia.
Comparison of non-participators with those still active in
the study showed no significant differences in HLA risk
group, relationship to proband or region. The non-
participation rate was highest at the beginning of the study
and declined thereafter.
The success of the study so far could be due, at least
partly, to the long-lasting collaboration of the investigators
and their good relations with staff at the clinical and other
sites.
Adverse events All adverse events were reported electron-
ically using on-line event monitoring systems developed
and supported by the DMU. Serious events were also
reported to the local IRB (according to local guidelines) and
the study Chair’s office. All adverse events, including those
categorised as serious, were reviewed at each DSMB
meeting. There have been no concerns regarding safety
issues and the study intervention to date. Growth data are
routinely monitored by the DSMB. No differences in
growth data (participant height, weight and BMI) by
treatment arm have been observed to date.
Discussion
The TRIGR Study successfully demonstrates the viability
of a properly powered international intervention trial aimed
at primary prevention of type 1 diabetes. Some major
accomplishments of the study include: (1) development of
an infrastructure-intensive clinical trial network tightly
linked to the secure, web-based, interactive DMU, thus
enabling accurate tracking of the study’s rapidly growing
blood sample repositories; (2) satisfactory recruitment rate,
which improved after an initial delay, with accruals
exceeding target rates for most of the final 3 years of
accrual; and (3) study-wide protocol compliance (measur-
ing visits, questionnaires and blood samples) 94%, adjusted
for dropouts (as of 31 May, 2010). The high level of quality
control is due to the combined efforts of the DMU staff,
European monitors, North American coordinators, the ICC
and the Nutritional Epidemiology Unit staff. In addition,
the participant retention rate remains strong, at 87% after
5 years (80% planned). The intervention phase was
successfully completed in mid-2007. Compliance with the
intervention resulted in all planning variables being met or
exceeded. Thus compliance with filling in and returning of
forms, and thereby with study centre visits currently
exceeds 96%, whereas the expected rate was set at more
than 80%.
Compliance with the intervention was meticulously
implemented, monitored and recorded. This was accom-
plished by ongoing training at every level, coordinated
regionally using electronic, telephone and face to face
formats, with initial bi-annual and then annual Principal
Investigator, study nurse and dietitian meetings. The
experience gained during the second TRIGR pilot study
[3] was invaluable in the development of all protocols and
training procedures. Close interaction among study inves-
tigators, nurses and research participants was assured,
thanks to continuous liaison. Complementary to the
international and national websites, TRIGR Newsletters
and TRIGR Nutrition Newsletters containing relevant
information on the study progress have been distributed to
TRIGR staff members and families.
The role of the DMU was central in providing ongoing
training to sites and ensuring participation in regularly
scheduled conference calls with study coordinators/mon-
itors. The production of daily recruitment reports and
monthly compliance reports has provided constant feedback
and encouraged the clinical sites to continuously monitor
and improve their own performance in the study.
HLA eligibility ranged from 36.5% (Hungary) to 52.0%
(Switzerland) and was, on average, very similar in Europe
and North America (Table 1). The total rate of 43.2% was
only slightly lower than the expected 45.0%, and we
compensated for the difference by enrolling somewhat
more participants than originally planned. Offspring of
affected fathers have about a twofold higher risk of
developing type 1 diabetes than offspring of affected
mothers [10, 11]. From that point of view it would be
preferable to recruit offspring of affected fathers for
intervention trials aimed at prevention of clinical disease,
as the frequency of clinical endpoints would be higher.
However, in most countries it is more difficult to identify
prospective fathers with type 1 diabetes than it is to identify
pregnant women (i.e. prospective mothers) with the disease.
In the TRIGR cohort, the proportion of fathers with type 1
diabetes was on average 34%, ranging from 8.7% in
Hungary to 53.4% in Finland, possibly reflecting differ-
ences in the structure and function of these countries’
healthcare systems.
The first endpoint of TRIGR, i.e. positivity for two or
more type 1 diabetes-associated autoantibodies and/or
clinical diabetes by the age of 6 years, will be reached in
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early 2013, when the youngest recruited participant turns
6 years. Autoantibody results are sent to the families after
the 6-year visit. The Study Protocol states that the OGTT
tests are done in all children at the ages of 6 and 10 years.
The study group has concluded that autoantibody-positive
participants cannot be denied participation in any secondary
prevention study. On the other hand, most such study
protocols tend to exclude individuals who have participated
in any earlier prevention trial. The primary and final
endpoint of TRIGR, i.e. clinical diabetes by the age of
10 years, will be reached early in 2017. The randomisation
codes will be opened when the last recruited child reaches
the age of 10 years, i.e. in 2017.
There are two possible scenarios in terms of the trial
outcome. If the intervention works and significantly
reduces the cumulative incidence of type 1 diabetes by
the age of 10 years, this would imply that infants at
increased risk of type 1 diabetes should be weaned to a
highly hydrolysed formula. If the intervention has no effect,
the study recommendation would state that weaning to a
highly hydrolysed formula does not decrease the risk of
type 1 diabetes, and accordingly such formulas do not
provide any benefits to infants carrying increased genetic
susceptibility to the disease. The international TRIGR study
is powered to provide a definite answer to the controversial
question of whether weaning to a hydrolysed formula
protects against initiation and progression of type 1
diabetes. This is the first-ever primary prevention trial for
type 1 diabetes. If the main hypothesis of the study is
proven to be correct, primary prevention of at least some
cases of type 1 diabetes and reduction of the associated
morbidity and mortality rates, and healthcare costs could
become a realistic goal. This seemingly innocuous strategy
could be applied to the general population with increased
genetic risk, from which some 90% of new cases of type 1
diabetes are derived [12].
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